Tools for Practice Outils pour la pratique


#293 Bath Time: Atopic Dermatitis and Bathing


CLINICAL QUESTION
QUESTION CLINIQUE
Can atopic dermatitis (AD) be improved with more baths/showers, bleach baths, or bath additives?


BOTTOM LINE
RÉSULTAT FINAL
In AD, more frequent baths (and likely showers), 1-2 times/day, improve symptoms meaningfully (≥30%) for about 40% more patients than less frequent bathing (with moisturizers after bath/showers). Despite advocacy, research does not support bleach baths, bath additives or water softeners for AD symptoms. Offer simple advice for frequent plain-water bathing and application of moisturizers immediately afterward.



CFPCLearn Logo

Reading Tools for Practice Article can earn you MainPro+ Credits

La lecture d'articles d'outils de pratique peut vous permettre de gagner des crédits MainPro+

Join Now S’inscrire maintenant

Already a CFPCLearn Member? Log in

Déjà abonné à CMFCApprendre? Ouvrir une session



EVIDENCE
DONNÉES PROBANTES
  • Statistically significant differences unless noted.
  • Frequency:
    • Cross-over randomized controlled trial (RCT)1 of 42 children with moderate-severe AD. Two-week treatments of twice-daily versus twice-weekly baths (moisturizers applied after baths but otherwise twice-daily):
      • Patients with ≥30% symptom improvement: 58% twice-daily baths versus 15% twice-weekly, number needed to treat (NNT)=3.
      • Mean symptom score (0-103, higher worse): Baseline 42, twice-daily baths improved 21 points more than twice-weekly.
  • Showers versus Baths:
    • No RCTs.
    • 1 non-randomized trial2 and 1 intervention cohort3: Children who added a shower daily at school had improved AD scores.
  • Bleach Baths:
    • General AD: Systematic Review4 (4 RCTs, 116 patients) of moderate-severe AD, bleach bath (5-10 mins, 2x/week) versus regular bath, at 4 weeks:
      • No significant difference in AD scores, surface area with AD, or staphylococcal colonization.
      • Limitations: Trials small/short/heterogeneous.
      • Others find similar.5 No increased adverse events.
    • AD with clinical bacterial infection:
      • RCT (22 patients): Reduction in score of submerged sites.
        • Bleach bath group also got nasal mupirocin and were more severe at start.6
      • Cross-over RCT (40 patients): No difference in AD severity.7
  • Additives (like Oilatum™ or Aveeno™):
    • Systematic review (5 RCTs, 111 patients):8 inconsistent reporting, high risk of bias.
    • RCT (482 children):9 generally moderate AD, assigned to bath additive (clinician/patient choice) versus no additive, after 1 year: No benefit.
  • Water Softener:
    • RCT (336 children):10 moderate-severe AD living in hard-water area (≥200 mg/l calcium carbonate), ion-filter water softener versus none, after 12 weeks: No difference.
Context
  • Guidelines/reviews recommend regular bathing and apply moisturizers (ointment or thick-creams) immediately after, while skin is still damp.11-14 
  • Advocacy for bath alterations, like bleach baths, persists11-14 but some acknowledge the evidence does not support benefit.13


david saunders June 28, 2021

will be applicable in practice

Steven Hobson July 5, 2021

Against previous recomendations….excellent

Charles Jiang August 18, 2021

Thank you.

Olukayode Fawole August 29, 2021

Good to know

YS Son December 8, 2021

I am surprised by this. Why frequent bathing helps AD?

othman elfahad December 29, 2021

thank you

Giuliano Pomalaza June 17, 2022

Answer to YS Son’s question from the AAD guideline: “Bathing can have differing effects on the skin depending on the manner in which it is carried out. Bathing with water can hydrate the skin and remove scale, crust, irritants, and allergens, which can be helpful for patients with AD.23 However, if the water is left to evaporate from the skin, greater transepidermal water loss occurs.24 Therefore, application of moisturizers soon after bathing is necessary to maintain good hydration status.”


Latest Tools for Practice
Derniers outils pour la pratique

#379 Bumpin’ Up the Protection? RSV Vaccine in Pregnancy

How effective and safe is the respiratory syncytial virus (RSV) vaccine (AbrysvoTM) when given during pregnancy?
Read Lire 0.25 credits available Crédits disponibles

#378 Tony Romo-sozumab: Winning touchdown in osteoporosis or interception for the loss?

What is the efficacy and safety of romosozumab in postmenopausal women with osteoporosis?
Read Lire 0.25 credits available Crédits disponibles

#377 How to slow the flow IV: Combined oral contraceptives

In premenopausal heavy menstrual bleeding due to benign etiology, do combined oral contraceptives (COC) improve patient outcomes?
Read Lire 0.25 credits available Crédits disponibles

This content is certified for MainPro+ Credits, log in to access

Ce contenu est certifié pour les crédits MainPro+, Ouvrir une session


Author(s)
Auteur(s)
  • G. Michael Allan MD CCFP
  • Rodger Craig MPH
  • Christina Korownyk MD CCFP

1. Cardona ID, Kempe EE, Lary C, et al. J Allergy Clin Immunol Pract. 2020 Mar; 8(3):1014-1021.

2. Kameyoshi Y, Tanaka T, Mochizuki M, et al. Arerugi 2008; 57(2):130-7

3. Mochizuki H, Muramatsu R, Tadaki H, et al. Pediatr Dermatol Mar-Apr 2009; 26(2):223-5.

4. Chopra R, Vakharia PP, Sacotte R, et al. Ann Allergy Asthma Immunol. 2017 Nov; 119(5):435-440.

5. George SM, Karanovic S, Harrison DA, et al. Cochrane Database Syst Rev. 2019; 2019(10):CD003871.

6. Huang JT, Abrams M, Tlougan B, et al. Pediatrics. 2009; 123:e808-e814.

7. Hon KL, Tsang YC, Lee VW, et al. J Dermatolg Treat. 2016; 27:156-162.

8. Maarouf M, Hendricks AJ, Shi VY. Dermatitis. 2019 May/Jun; 30(3):191-197.

9. Santer M, Ridd MJ, Francis NA, et al. BMJ. 2018 May 3; 361:k1332.

10. Thomas KS, Dean T, O'Leary C, et al. PLoS Med. 2011 Feb 15;8(2):e1000395.

11. Frazier W, Bhardwaj N. Am Fam Physician. 2020 May 15; 101(10):590-8.

12. Lynde C, Barber K, Claveau J, et al. J Cutan Med Surg. 2005; 8 Suppl 5:1-9. Weston WL, Howe W. Treatment of Atopic Dermatitis (eczema). UptoDate. www.uptodate.com Accessed May 9, 2021.

13. Katoh N, Ohya Y, Ikeda M, et al. Clinical practice guidelines for the management of atopic dermatitis 2018. J Dermatol. 2019 Dec; 46(12):1053-1101

Authors do not have any conflicts of interest to declare.

Les auteurs n’ont aucun conflit d’intérêts à déclarer.